Emerging data from a phase 2 clinical trial of adult patients with relapsed/refractory B-cell lymphomas treated with axicabtagene ciloleucel (CD19CART immunotherapy) has further demonstrated reduced frequency and severity of inflammatory sequelae in patients randomized to co-treatment with the selective JAK1 inhibitor itacitinib as CRS prophylaxis compared to placebo control [53]. The gene discussed is JAK1; the disease is congenital rubella syndrome.